Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2010

01.12.2010 | Research Paper

p-AKT overexpression in primary renal cell carcinomas and their metastases

verfasst von: Martina Hager, Heike Haufe, Lukas Lusuardi, Nikolaus Schmeller, Christian Kolbitsch

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

In cancer therapy novel concepts focus on phosphoinositide 3-kinase (PI3K)/activated protein kinase B (p-AKT)/mammalian target of rapamycin (mTOR) inhibitors. In this context, p-AKT overexpression was previously shown to be associated with sensitivity to inhibitors of mTOR. The present study evaluated p-AKT expression in a tissue microarray of primary renal cell carcinomas (PRCCs) (n = 45), their metastases (primary onset n = 45, secondary onset n = 5), and normal renal parenchyma (n = 45) by means of immunohistochemistry. Total p-AKT overexpression was found in 24/45 (53.3%) PRCCs, in 32/45 (71.1%) primary and in 3/5 (60%) secondary onset metastases. Membranous p-AKT overexpression was seen more frequently in PRCCs, namely 11/45 (24.4%), than in primary onset metastases 1/45 (2.2%). Overexpression of total p-AKT solely in metastases without overexpression in PRCC was exclusively demonstrated in primary onset metastases, namely in 28.9%. Patients with total p-AKT overexpression in primary carcinomas showed a trend to longer, and those with total p-AKT overexpression in metastases a tendency to shorter survival. In conclusion, the present study shows total p-AKT overexpression to be more frequent in metastases than in PRCCs. Total p-AKT overexpression in metastases without concomitant overexpression in their primary tumors was found in approximately one-third of primary onset metastases, which is interesting with regard to the association between high p-AKT expression and sensitivity to mTOR inhibitor therapy.
Literatur
1.
Zurück zum Zitat Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMed Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281CrossRefPubMed
2.
Zurück zum Zitat Kapoor A, Figlin RA (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 115:3618–3630CrossRefPubMed Kapoor A, Figlin RA (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 115:3618–3630CrossRefPubMed
3.
Zurück zum Zitat Merseburger AS, Kuczyk MA (2008) Value of targeted therapies for renal cell cancer. Urologe A 47:1303–1310CrossRefPubMed Merseburger AS, Kuczyk MA (2008) Value of targeted therapies for renal cell cancer. Urologe A 47:1303–1310CrossRefPubMed
4.
Zurück zum Zitat Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379–385CrossRefPubMed Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379–385CrossRefPubMed
5.
Zurück zum Zitat Porta C, Figlin RA (2007) Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol 182:2569–2577CrossRef Porta C, Figlin RA (2007) Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol 182:2569–2577CrossRef
6.
Zurück zum Zitat Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M (2005) Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16:928–933CrossRefPubMed Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M (2005) Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16:928–933CrossRefPubMed
7.
Zurück zum Zitat Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905–2927CrossRefPubMed Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905–2927CrossRefPubMed
8.
9.
Zurück zum Zitat Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245CrossRefPubMed Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245CrossRefPubMed
10.
Zurück zum Zitat Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339–345PubMed Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339–345PubMed
11.
Zurück zum Zitat Manning BD, Cantley LC (2003) Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 28:573–576CrossRefPubMed Manning BD, Cantley LC (2003) Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 28:573–576CrossRefPubMed
12.
Zurück zum Zitat Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797–803CrossRefPubMed Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797–803CrossRefPubMed
13.
Zurück zum Zitat David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10:6865–6871CrossRefPubMed David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10:6865–6871CrossRefPubMed
14.
Zurück zum Zitat Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL, Kolbitsch C (2009) Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 13:2181–2188CrossRefPubMed Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL, Kolbitsch C (2009) Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 13:2181–2188CrossRefPubMed
15.
Zurück zum Zitat Horiguchi A, Oya M, Uchida A, Marumo K, Murai M (2003) Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 169:710–713CrossRefPubMed Horiguchi A, Oya M, Uchida A, Marumo K, Murai M (2003) Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 169:710–713CrossRefPubMed
16.
Zurück zum Zitat Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A (2001) The AKT kinase is activated in multiple myeloma tumor cells. Blood 98:2853–2855CrossRefPubMed Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A (2001) The AKT kinase is activated in multiple myeloma tumor cells. Blood 98:2853–2855CrossRefPubMed
17.
Zurück zum Zitat Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236CrossRefPubMed Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232–5236CrossRefPubMed
18.
Zurück zum Zitat Massarelli E, Liu DD, Lee JJ, El Naggar AK, Lo ML, Staibano S, De Placido S, Myers JN (2005) Akt activation correlates with adverse outcome in tongue cancer. Cancer 104:2430–2436CrossRefPubMed Massarelli E, Liu DD, Lee JJ, El Naggar AK, Lo ML, Staibano S, De Placido S, Myers JN (2005) Akt activation correlates with adverse outcome in tongue cancer. Cancer 104:2430–2436CrossRefPubMed
19.
Zurück zum Zitat Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105–6111PubMed Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61:6105–6111PubMed
20.
Zurück zum Zitat Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L, Rutqvist LE (2003) Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5:R37–R44CrossRefPubMed Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L, Rutqvist LE (2003) Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5:R37–R44CrossRefPubMed
21.
Zurück zum Zitat Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, Aozasa K (2006) Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12:3070–3077CrossRefPubMed Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, Aozasa K (2006) Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12:3070–3077CrossRefPubMed
22.
Zurück zum Zitat Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H, Terakawa N (2005) PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 14:389–392PubMed Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H, Terakawa N (2005) PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 14:389–392PubMed
23.
Zurück zum Zitat Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K (2004) Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10:2846–2850CrossRefPubMed Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K (2004) Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10:2846–2850CrossRefPubMed
24.
Zurück zum Zitat Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663CrossRefPubMed Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663CrossRefPubMed
25.
Zurück zum Zitat Eble JN, Sauter G, Epstein JI, Sesterhenn A (2004) WHO classification of tumours. Tumors of the urinary system and male genital organs, IARC Press, Lyon Eble JN, Sauter G, Epstein JI, Sesterhenn A (2004) WHO classification of tumours. Tumors of the urinary system and male genital organs, IARC Press, Lyon
26.
Zurück zum Zitat Park JY, Lin PY, Weiss RH (2007) Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther 7:863–870CrossRefPubMed Park JY, Lin PY, Weiss RH (2007) Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther 7:863–870CrossRefPubMed
27.
Zurück zum Zitat He L, Fan C, Gillis A, Feng X, Sanatani M, Hotte S, Kapoor A, Tang D (2007) Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim Biophys Acta 1772:1134–1142PubMed He L, Fan C, Gillis A, Feng X, Sanatani M, Hotte S, Kapoor A, Tang D (2007) Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim Biophys Acta 1772:1134–1142PubMed
28.
Zurück zum Zitat Motzer RJ, Escudier B, Oudard S, Hutson T, Porta C, Bracarda S, Grünwald V, Thompson J, Figlin R, Hollaender N, Urbanowitz G, Berg W, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMed Motzer RJ, Escudier B, Oudard S, Hutson T, Porta C, Bracarda S, Grünwald V, Thompson J, Figlin R, Hollaender N, Urbanowitz G, Berg W, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMed
29.
Zurück zum Zitat Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12:7215–7220CrossRefPubMed Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12:7215–7220CrossRefPubMed
30.
Zurück zum Zitat Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F (2008) Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112:2352–2358CrossRefPubMed Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F (2008) Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112:2352–2358CrossRefPubMed
31.
Zurück zum Zitat Frost P, Shi Y, Hoang B, Lichtenstein A (2007) AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26:2255–2262CrossRefPubMed Frost P, Shi Y, Hoang B, Lichtenstein A (2007) AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 26:2255–2262CrossRefPubMed
32.
Zurück zum Zitat Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric Bernstam F (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013–1023CrossRefPubMed Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric Bernstam F (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013–1023CrossRefPubMed
33.
Zurück zum Zitat Huang WC, Hung MC (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108:180–194CrossRefPubMed Huang WC, Hung MC (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108:180–194CrossRefPubMed
34.
Zurück zum Zitat Pollock RE, Lang A, Luo J, El Naggar AK, Yu D (1996) Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 12:2035–2039PubMed Pollock RE, Lang A, Luo J, El Naggar AK, Yu D (1996) Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 12:2035–2039PubMed
35.
Zurück zum Zitat Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos F, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane H, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603–1610CrossRefPubMed Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos F, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane H, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603–1610CrossRefPubMed
36.
Zurück zum Zitat Amin MB, Paner GP, Alvarado-Cabrero I, Young A, Stricker HJ, Lyles RH, Moch H (2008) Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32:1822–1834CrossRefPubMed Amin MB, Paner GP, Alvarado-Cabrero I, Young A, Stricker HJ, Lyles RH, Moch H (2008) Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32:1822–1834CrossRefPubMed
37.
Zurück zum Zitat Beck SD, Manish I, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo P (2004) Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11:71–77CrossRefPubMed Beck SD, Manish I, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo P (2004) Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11:71–77CrossRefPubMed
38.
Zurück zum Zitat Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20:375–381CrossRefPubMed Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20:375–381CrossRefPubMed
Metadaten
Titel
p-AKT overexpression in primary renal cell carcinomas and their metastases
verfasst von
Martina Hager
Heike Haufe
Lukas Lusuardi
Nikolaus Schmeller
Christian Kolbitsch
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2010
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9351-y

Weitere Artikel der Ausgabe 8/2010

Clinical & Experimental Metastasis 8/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.